Search

Twenty five adult patients with minimal changes disease proven at kidney biopsy and 13 of them older than 50 years of age are reported. Clinically, 32% of cases behaved as "impure" nephrotic syndrome, with no one case of established renal insufficiency; in nine cases, the process was antedated by a triggering event, usually infective episodes. In four cases who received no treatment, spontaneous remission was observed. All treated patients but one, initially responded to corticosteroid treatment in a period shorter than 1 month and 40% of patients presented maintained remission. There were no important complications derived from the disease nor from the treatment and at the end of the follow up only one patient died from a disease unrelated to the nephropathy.

Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (CKD) patients. Cinacalcet could be a therapeutic option although its use is controversial in patients not receiving dialysis. Thus, the aim of this study is to assess the effectiveness and safety of cinacalcet in patients with CKD and SHPT without renal replacement treatment (RRT) and without renal transplantation (RT). Methods A retrospective observational study was conducted. Patients were included if they had collected cinacalcet, under off-label use, during 2010 and 2011. Patients selected were followed from the beginning of cinacalcet therapy for one year of treatment. Results A total of 37 patients were included with CKD stage 3 (38%), 4 (51%) and 5 (11%). Baseline mean PTH value was 400.86 ± 168.60 mg/dl. At 12 months, a 67% of patients achieved at least a 30% reduction in their PTH value (p